Circulating tumor cells (CTC) are detached from a primary tumor and enter the circulation or lymphatic system, permitting them to circulate within the body. They are present in the peripheral blood of cancer patients and are released by solid tumors. When cancer spreads from the primary tumor to other organs, a process known as metastasis, CTCs play a crucial role. As CTCs provide a non-invasive method for tracking the progression of the disease, predicting treatment efficacy, and determining prognosis, they are of great interest to cancer research and clinical practice. By extracting and analyzing CTCs, a great deal can be learned about the characteristics of the tumor, including genetic alterations, protein expression, and drug resistance patterns. This data can aid in formulating targeted therapy and treatment decisions for patients. CTCs are uncommon, and common blood cells are present in blood samples, making it difficult to isolate and detect CTCs.
Chip technology has significantly impacted the market, particularly in capturing circulating tumor cells (CTCs). Cluster chip technology is used to achieve accurate CTC isolation and address the challenges isolation devices face. However, these devices face challenges such as low sensitivity, inability to capture different sizes and shapes, high production costs, and difficulty removing collected CTCs for laboratory examination. Additionally, white blood cells infecting CTCs may be mistaken for CTCs due to their similar size. As a result, there is a growing demand for personalized cancer prevention medications. Researchers have found that cluster-chip technology is more effective than microfluidic chips, which use antibodies to isolate CTCs on tumor cell surfaces. This technology has no negative effect on CTC clusters, accelerating the development of CTC isolation chips and driving revenue growth.
There are enormous opportunities for liquid biopsy market expansion in developing nations such as India, Brazil, Turkey, Russia, South Africa, China, and South Korea. Among these nations are South Africa, China, and South Korea. These nations include South Korea, China, South Africa, and South Africa. In addition, these nations provide a substantial number of opportunities. Several distinct factors can be attributed to the expanding market for liquid biopsies in developing nations. The most significant of these factors are a strengthening healthcare infrastructure, an increase in the number of people diagnosed with cancer, a substantial patient population, an increase in disposable income, and the expansion of the medical tourism industry. Consequently, the market has many potential growth opportunities in the coming years.
North America is the most significant global circulating tumor cells CTCs market shareholder and is estimated to exhibit a CAGR of 11.38% over the forecast period. The prevalence of cancer in North America is anticipated to drive the market in this region. Increased awareness and enhanced cancer treatment healthcare facilities are the market's most important drivers. Continuous technological advancements, followed by the discovery of novel antigens and biomarkers, are responsible for the predicted expansion of the CTC testing market. In addition to sophisticated facilities and extensive research, the market expansion is bolstered by additional crucial factors. In addition, the local presence of key players and research institutions working to improve CTC testing kits, a well-defined reimbursement structure, and advancements in related technologies, such as personalized medicine, drug discovery, cancer diagnostics, and liquid biopsy, is anticipated to stimulate market growth. For example, researchers at the Cleveland Clinic in Ohio have developed new liquid biopsy tests that can aid in cancer diagnosis before the advent of symptoms. Such developments are anticipated to stimulate the expansion of the North American CTC market.
Asia-Pacific is anticipated to exhibit a CAGR of 13.21% over the forecast period. The growth of the Asia Pacific CTC market is anticipated to be fueled by an increase in cancer incidence and mortality rates in the region's middle- and low-income countries due to an aging population and lifestyle changes associated with epidemiologic transition and economic development. Breast, lung, uterine cervix, lip, oral cavity, and colorectum cancer are the most prevalent malignancies in the region. In addition, cancer mortality and incidence rates vary substantially across Asia-Pacific subregions. According to The Cancer Atlas, eastern, southern, and southeastern Asia account for 44% of all cancer cases and 51% of all cancer fatalities worldwide. China has the greatest incidence of cancer in Asia, followed by Japan, India, South Korea, and Indonesia. The market is driven by improving developing nations' cancer management and diagnosis systems.
The key players in the global circulating tumor cells CTCs market QIAGEN; Bio-Techne Corporation; Precision for Medicine; AVIVA Biosciences; BIOCEPT, Inc.; BioCEP Ltd.; Fluxion Biosciences, Inc.; Greiner Bio-One International GmbH; Ikonisys Inc.; Miltenyi Biotec; IVDiagnostics; BioFluidica; Canopus Bioscience Ltd.; Biolidics Limited; Creativ MicroTech, Inc.; LungLife AI, Inc.; Epic Sciences; Rarecells Diagnostics; ScreenCell; Menarini Silicon Biosystems; LineaRx, Inc. (Vitatex, Inc.); Sysmex Corporation; and STEMCELL Technologies, Inc.